10O First-in-human, dose escalation of MT-8421: A novel engineered toxin body (ETB) targeting CTLA-4, in patients with select advanced solid tumors
MT-8421 is an engineered toxin body (ETB) combining a Shiga-like Toxin A (SLT-A) subunit with two anti-CTLA4 VHH fragments. By exploiting SLT-A’s internalization and ribosomal toxicity, MT-8421 targets CTLA-4-expressing regulatory T cells in the tumor microenvironment for destruction while aiming to minimize peripheral immune-related adverse events seen with approved anti-CTLA4 monoclonal antibodies.
Authors
- Inderjit Mehmi (ORCID: https://orcid.org/0000-0002-2253-2206)
- Eric Poma
- Omid Hamid (ORCID: https://orcid.org/0000-0002-8238-4655)
- Satyendra Kumar Singh (ORCID: https://orcid.org/0000-0001-6795-670X)
- Kristina Dabovic
- B.A. Van Tine
- A.C. Pavlick
- Jedd D. Wolchok (ORCID: https://orcid.org/0000-0001-6718-2222)
- Justin T. Moyers (ORCID: https://orcid.org/0000-0001-5139-1652)
- C. J. Moore (ORCID: https://orcid.org/0000-0002-2527-0213)
- Soratree Charoenthongtrakul
- Sharad Chandra
- S. K. Khanna (ORCID: https://orcid.org/0000-0002-7587-594X)
- A. Spira
Institutions
- Cancer Treatment Centers of America (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Angeles Clinic and Research Institute (US)
- Molecular Templates (United States) (US)
- Virginia Cancer Specialists (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104166
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00